Exelixis Inc. Insider Trading

EXEL

Last 12 months

Insiders sold $42.2M and bought nothing on the open market.

16% of the selling was scheduled in advance under 10b5-1 plans. Director Julie Smith sold $4.69M on Feb 18, 84% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−$42.2M

0 buys · 23 sales

Under a 10b5-1 plan

16%

of the value sold

Insiders who bought / sold

0 / 12

executives and directors

Last open-market buy

May 2024

May 30, 2024

Get an email when EXEL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 10	Mary C Beckerle Director	Sold10b5-1 plan	9,812	$53.66	527K	38%	Form 4
Jun 1	Jack L Wyszomierski Director	Sold10b5-1 plan	3,925	$50.55	198K	1.4%	Form 4
Jun 1	Sue Gail Eckhardt Director	Sold10b5-1 plan	9,812	$50.14	492K	38%	Form 4
May 26	Dana Aftab EVP, Research and Development	SoldNo plan	43,451	$50.35	$2.19M	6.7%	Form 4
May 20	Patrick J. Haley EVP, Commercial	SoldNo plan	32,110	$49.81	$1.6M	8.2%	Form 4
May 18	Christopher J. Senner EVP and CFO	SoldNo plan	34,901	$50.00	$1.75M	3.5%	Form 4
May 18	Brenda Hefti SVP and General Counsel	Sold10b5-1 plan	6,625	$50.21	333K	5.6%	Form 4
May 7	Mary C Beckerle Director	SoldNo plan	7,712	$48.45	374K	31%	Form 4
May 7	Maria C Freire Director	SoldNo plan	20,634	$46.00	949K	17%	Form 4
May 7	George Poste Director	SoldNo plan	60,000	$45.71	$2.74M	34%	Form 4
Feb 24	Dana Aftab EVP, Research and Development	SoldNo plan	47,918	$44.50	$2.13M	7.2%	Form 4
Feb 19	Dana Aftab EVP, Research and Development	SoldNo plan	29,873	$44.35	$1.32M	4.3%	Form 4
Feb 18	Jack L Wyszomierski Director	Sold10b5-1 plan	99,574	$44.01	$4.38M	26%	Form 4
Feb 17 – 18	Julie Smith Director	SoldNo plan 3 parts	106,539	$44.00 average	$4.69M	84%	Form 4
Feb 18	Brenda Hefti SVP and General Counsel	Sold10b5-1 plan	18,669	$44.01	822K	15%	Form 4
Feb 13 – 17	Christopher J. Senner EVP and CFO	SoldNo plan 2 parts	64,895	$43.32 average	$2.81M	6.2%	Form 4
Feb 17	Patrick J. Haley EVP, Commercial	SoldNo plan 2 parts	67,814	$43.52 average	$2.95M	15%	Form 4
Feb 13	Sue Gail Eckhardt Director	Sold10b5-1 plan	3,856	$43.79	169K	18%	Form 4
Feb 13	Bob Oliver Director	SoldNo plan 2 parts	30,250	$43.81 average	$1.33M	59%	Form 4
Nov 25, 2025	Caligan Partners LP Large holder	Bought	27,532	$43.12	$1.19M	1.8%	Form 4
Nov 20, 2025 – Nov 21, 2025	Patrick J. Haley EVP, Commercial	SoldNo plan 4 parts	72,230	$42.18 average	$3.05M	16%	Form 4
Nov 12, 2025	Stelios Papadopoulos Director	SoldNo plan	100,000	$43.55	$4.36M	7.8%	Form 4
Nov 11, 2025	Dana Aftab EVP, Research and Development	SoldNo plan	48,383	$42.50	$2.06M	6.7%	Form 4
Nov 11, 2025	Mary C Beckerle Director	SoldNo plan 2 parts	24,622	$41.93 average	$1.03M	54%	Form 4
Jun 3, 2025	Jack L Wyszomierski Director	Sold10b5-1 plan	7,535	$43.09	325K	2.1%	Form 4
Jun 2, 2025	Sue Gail Eckhardt Director	Sold10b5-1 plan 2 parts	18,838	$42.74 average	805K	47%	Form 4
May 21, 2025	Tomas J. Heyman Director	SoldNo plan	4,544	$44.29	201K	12%	Form 4
May 20, 2025	Patrick J. Haley EVP, Commercial	SoldNo plan	34,387	$44.06	$1.52M	7.2%	Form 4
May 16, 2025	George Poste Director	SoldNo plan	20,634	$45.99	949K	11%	Form 4
May 16, 2025	Christopher J. Senner EVP and CFO	SoldNo plan	100,000	$46.00	$4.6M	9.3%	Form 4
May 16, 2025	Amy C. Peterson EVP Prod Dev & Med Aff & CMO	SoldNo plan	72,776	$45.47	$3.31M	14%	Form 4
May 15, 2025	Stelios Papadopoulos Director	SoldNo plan 2 parts	36,508	$44.35 average	$1.62M	2.8%	Form 4
May 15, 2025	Jeffrey Hessekiel EVP & General Counsel	SoldNo plan	25,000	$46.18	$1.15M	3.5%	Form 4
May 14, 2025 – May 15, 2025	Patrick J. Haley EVP, Commercial	Sold10b5-1 plan 3 parts	136,383	$47.58 average	$6.49M	22%	Form 4
May 1, 2025	Dana Aftab CSO/EVP Disc & Trans Research	Sold10b5-1 plan	1,508	$39.00	59K	0.2%	Form 4
Mar 3, 2025	Patrick J. Haley EVP, Commercial	Sold10b5-1 plan	10,000	$38.80	388K	2.6%	Form 4
Feb 27, 2025 – Feb 28, 2025	Julie Smith Director	SoldNo plan 2 parts	73,808	$38.00 average	$2.8M	87%	Form 4
Feb 28, 2025	Jack L Wyszomierski Director	Sold10b5-1 plan	8,768	$37.80	331K	2.4%	Form 4
Feb 25, 2025	Bob Oliver Director	SoldNo plan	18,647	$37.25	695K	36%	Form 4
Feb 24, 2025	Patrick J. Haley EVP, Commercial	SoldNo plan	52,636	$36.98	$1.95M	13%	Form 4

Aug 1010b5-1 plan
Mary C Beckerle
Director · sold 9,812 at $53.66
527K
38% of stake
Jun 110b5-1 plan
Jack L Wyszomierski
Director · sold 3,925 at $50.55
198K
1.4% of stake
Jun 110b5-1 plan
Sue Gail Eckhardt
Director · sold 9,812 at $50.14
492K
38% of stake
May 26No plan
Dana Aftab
EVP, Research and Development · sold 43,451 at $50.35
$2.19M
6.7% of stake
May 20No plan
Patrick J. Haley
EVP, Commercial · sold 32,110 at $49.81
$1.6M
8.2% of stake
May 18No plan
Christopher J. Senner
EVP and CFO · sold 34,901 at $50.00
$1.75M
3.5% of stake
May 1810b5-1 plan
Brenda Hefti
SVP and General Counsel · sold 6,625 at $50.21
333K
5.6% of stake
May 7No plan
Mary C Beckerle
Director · sold 7,712 at $48.45
374K
31% of stake
May 7No plan
Maria C Freire
Director · sold 20,634 at $46.00
949K
17% of stake
May 7No plan
George Poste
Director · sold 60,000 at $45.71
$2.74M
34% of stake
Feb 24No plan
Dana Aftab
EVP, Research and Development · sold 47,918 at $44.50
$2.13M
7.2% of stake
Feb 19No plan
Dana Aftab
EVP, Research and Development · sold 29,873 at $44.35
$1.32M
4.3% of stake
Feb 1810b5-1 plan
Jack L Wyszomierski
Director · sold 99,574 at $44.01
$4.38M
26% of stake
Feb 17 – 18No plan
Julie Smith
Director · sold 106,539 at avg $44.00
$4.69M
84% of stake
Feb 1810b5-1 plan
Brenda Hefti
SVP and General Counsel · sold 18,669 at $44.01
822K
15% of stake
Feb 13 – 17No plan
Christopher J. Senner
EVP and CFO · sold 64,895 at avg $43.32
$2.81M
6.2% of stake
Feb 17No plan
Patrick J. Haley
EVP, Commercial · sold 67,814 at avg $43.52
$2.95M
15% of stake
Feb 1310b5-1 plan
Sue Gail Eckhardt
Director · sold 3,856 at $43.79
169K
18% of stake
Feb 13No plan
Bob Oliver
Director · sold 30,250 at avg $43.81
$1.33M
59% of stake
Nov 25, 2025
Caligan Partners LP
Large holder · bought 27,532 at $43.12
$1.19M
1.8% of stake
Nov 20, 2025 – Nov 21, 2025No plan
Patrick J. Haley
EVP, Commercial · sold 72,230 at avg $42.18
$3.05M
16% of stake
Nov 12, 2025No plan
Stelios Papadopoulos
Director · sold 100,000 at $43.55
$4.36M
7.8% of stake
Nov 11, 2025No plan
Dana Aftab
EVP, Research and Development · sold 48,383 at $42.50
$2.06M
6.7% of stake
Nov 11, 2025No plan
Mary C Beckerle
Director · sold 24,622 at avg $41.93
$1.03M
54% of stake
Jun 3, 202510b5-1 plan
Jack L Wyszomierski
Director · sold 7,535 at $43.09
325K
2.1% of stake
Jun 2, 202510b5-1 plan
Sue Gail Eckhardt
Director · sold 18,838 at avg $42.74
805K
47% of stake
May 21, 2025No plan
Tomas J. Heyman
Director · sold 4,544 at $44.29
201K
12% of stake
May 20, 2025No plan
Patrick J. Haley
EVP, Commercial · sold 34,387 at $44.06
$1.52M
7.2% of stake
May 16, 2025No plan
George Poste
Director · sold 20,634 at $45.99
949K
11% of stake
May 16, 2025No plan
Christopher J. Senner
EVP and CFO · sold 100,000 at $46.00
$4.6M
9.3% of stake
May 16, 2025No plan
Amy C. Peterson
EVP Prod Dev & Med Aff & CMO · sold 72,776 at $45.47
$3.31M
14% of stake
May 15, 2025No plan
Stelios Papadopoulos
Director · sold 36,508 at avg $44.35
$1.62M
2.8% of stake
May 15, 2025No plan
Jeffrey Hessekiel
EVP & General Counsel · sold 25,000 at $46.18
$1.15M
3.5% of stake
May 14, 2025 – May 15, 202510b5-1 plan
Patrick J. Haley
EVP, Commercial · sold 136,383 at avg $47.58
$6.49M
22% of stake
May 1, 202510b5-1 plan
Dana Aftab
CSO/EVP Disc & Trans Research · sold 1,508 at $39.00
59K
0.2% of stake
Mar 3, 202510b5-1 plan
Patrick J. Haley
EVP, Commercial · sold 10,000 at $38.80
388K
2.6% of stake
Feb 27, 2025 – Feb 28, 2025No plan
Julie Smith
Director · sold 73,808 at avg $38.00
$2.8M
87% of stake
Feb 28, 202510b5-1 plan
Jack L Wyszomierski
Director · sold 8,768 at $37.80
331K
2.4% of stake
Feb 25, 2025No plan
Bob Oliver
Director · sold 18,647 at $37.25
695K
36% of stake
Feb 24, 2025No plan
Patrick J. Haley
EVP, Commercial · sold 52,636 at $36.98
$1.95M
13% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EXEL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with EXEL

CompareIntrinsic value

INCYIncyte Corporation

$122.83+4.46%43

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

HALOHalozyme Therapeutics Inc.

$130.34+1.34%66

BMRNBiomarin Pharmaceutical Inc.

$57.13+2.64%47

NBIXNeurocrine Biosciences Inc.

$167.21+1.43%85

Held by ETFs

EXEL is in 213 US ETFs. The largest of them, with EXEL's weight in each:

Spot a number that looks wrong? Check it in EXEL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EXEL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.